CODA Biotherapeutics, a biopharmaceutical company developing a gene therapy approach for the treatment of neurological diseases, announced the acquisition of Attenua with its three clinical stage small molecule drugs. CODA has engineered a set of ligand-gated ion channels that can be specifically controlled by these drugs.
CODA plans to advance these unique channel-ligand pairs toward the clinic to treat neuropathic pain, focal epilepsy, and other neurologic diseases and disorders.
Read more about CODA Biotherapeutics here.
Image by Gerd Altmann from Pixabay
